Jump to Main Content

Clinicians

FDA Approves Dalteparin Sodium for VTE in Pediatric Patients

The Food and Drug Administration approved dalteparin sodium (FRAGMIN, Pfizer, Inc.) to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients 1 month of age and older.
Citations